Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Artiva Biotherapeutics (ARTV) Capital Expenditures: 2023-2025

Historic Capital Expenditures for Artiva Biotherapeutics (ARTV) over the last 2 years, with Sep 2025 value amounting to $600,000.

  • Artiva Biotherapeutics' Capital Expenditures rose 525.00% to $600,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.2 million, marking a year-over-year increase of 83.69%. This contributed to the annual value of $642,000 for FY2024, which is 80.29% down from last year.
  • Artiva Biotherapeutics' Capital Expenditures amounted to $600,000 in Q3 2025, which was down 12.28% from $684,000 recorded in Q2 2025.
  • Artiva Biotherapeutics' 5-year Capital Expenditures high stood at $882,000 for Q1 2025, and its period low was $18,000 during Q1 2024.
  • Moreover, its 3-year median value for Capital Expenditures was $464,000 (2024), whereas its average is $402,556.
  • Per our database at Business Quant, Artiva Biotherapeutics' Capital Expenditures tumbled by 89.94% in 2024 and then skyrocketed by 4,800.00% in 2025.
  • Quarterly analysis of 3 years shows Artiva Biotherapeutics' Capital Expenditures stood at $636,000 in 2023, then slumped by 89.94% to $64,000 in 2024, then surged by 525.00% to $600,000 in 2025.
  • Its Capital Expenditures was $600,000 in Q3 2025, compared to $684,000 in Q2 2025 and $882,000 in Q1 2025.